Top > Search of International Patents > PROPHYLACTIC OR THERAPEUTIC DRUG FOR INFARCTION DISEASE

PROPHYLACTIC OR THERAPEUTIC DRUG FOR INFARCTION DISEASE commons

Foreign code F150008420
Posted date Oct 9, 2015
Country WIPO
International application number 2014JP051202
International publication number WO 2014119438
Date of international filing Jan 22, 2014
Date of international publication Aug 7, 2014
Priority data
  • P2013-014263 (Jan 29, 2013) JP
Title PROPHYLACTIC OR THERAPEUTIC DRUG FOR INFARCTION DISEASE commons
Abstract Provided is a therapeutic drug for an infarction disease, in particular, a drug that is capable of exhibiting a therapeutic effect on the infarction disease even in the case where said drug is administered 3 hours or longer after the onset of regional ischemia. A prophylactic or therapeutic drug for an infarction disease, said drug containing an RANKL protein.
Outline of related art and contending technology BACKGROUND ART
The disease is cerebral infarction such as myocardial infarction or infarcted, ischemic vascular occlusion or the like due to the occurrence of the site. Typically, ischemia having a portion in such a way that a portion of the perimeter and thus can encourage the oxygen and nutrient, further at the same time or in accordance with this inflammatory response occurs by free radical production, increased with necrosis site a short period of time. Therefore, for the treatment of diseases is infarct, ischemia after the occurrence of the site, administering a therapeutic effective at a relatively early stage is extremely important.
As such therapeutic agents, internationally recognized effectiveness include, for example thrombolytic drugs (tissue plasminogen activator) has been known. However, the thrombolytic agent is, after the occurrence of the ischemic site within 3 since the time required to be administered, the time of occurrence of ischemic site which has already been completely unknown patient 3 time passes after the occurrence of the ischemic site and cannot be used by the patient. Therefore, after the occurrence of the ischemic site after time passes 3 administered infarcted disease development of therapeutics to exert effects is demanded.
RANKL(Receptor Activator of NF κB Ligand) activating osteoclasts promote bone resorption by well known as a factor. In part, in order to inhibit the inflammatory cytokine RANKL is reported (non-patent document 1) but, in the first place RANKL is, as its name indicates NFκB (inflammatory cytokine IL-6 and having a function of promoting the expression of TNF α) was discovered as a factor for activating since, and inhibit inflammatory responses actually RANKL infarction diseases whether or not the therapeutic effect is unknown. In addition, inhibit inflammatory responses to steroid therapy is effective against diseases not infarcted in view of these circumstances, it is possible to suppress the inflammatory response simply infarct effective for the treatment of diseases is unknown whether any of the said.
Scope of claims (In Japanese)請求の範囲 [請求項1]
RANKLタンパク質を含有する梗塞性疾患の予防又は治療用医薬。

[請求項2]
梗塞性疾患が梗塞である請求項1に記載の予防又は治療用医薬。

[請求項3]
梗塞性疾患が脳梗塞、心筋梗塞、肺梗塞、腎梗塞、下肢急性動脈閉塞症、及びクモ膜下出血後の血管攣縮による脳梗塞からなる群より選択される少なくとも1種である請求項1又は2に記載の予防又は治療用医薬。

[請求項4]
RANKLタンパク質が下記(e)に記載するタンパク質及び下記(f)に記載するタンパク質からなる群より選択される少なくとも1種である請求項1~3のいずれかに記載の予防又は治療用医薬:
(e)配列番号3又は4に示されるアミノ酸配列からなるタンパク質、
(f)配列番号3又は4に示されるアミノ酸配列と85%以上の同一性を有するアミノ酸配列からなり、且つRANKタンパク質結合活性を有するタンパク質。

[請求項5]
RANKLタンパク質が配列番号3又は4に示されるアミノ酸配列からなるタンパク質である請求項4に記載の予防又は治療用医薬。

[請求項6]
皮下投与剤、経動脈投与剤、又は経静脈投与剤である請求項1~5のいずれかに記載の予防又は治療用医薬。

[請求項7]
梗塞性疾患の予防又は治療において使用されるための、RANKLタンパク質。

[請求項8]
請求項1~6のいずれかに記載の予防又は治療用医薬を、梗塞性疾患患者若しくは梗塞性疾患を発症する可能性がある被検体に投与することを包含する、梗塞性疾患の予防又は治療方法。

  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • OSAKA UNIVERSITY
  • Inventor
  • SHIMAMURA, Munehisa
  • NAKAGAMI, Hironori
  • OSAKO, Mariana Kiomy
  • MORISHITA, Ryuichi
  • KURINAMI, Hitomi
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close